Clinical Trial Update: Tolerability and Safety of Subcutaneous Administration of Two Doses of AFFITOPE® PD01A in Early Parkinson's Disease [Phase 1]

View source ↗

Summary

Phase 1 trial update evaluating tolerability and safety of two subcutaneous doses of AFFITOPE PD01A in early Parkinson's disease. The study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• AFFITOPE PD01A (PD01A)

Snippet

Sponsor: Affiris AG | Conditions: Parkinson's Disease | Phase 1 | Status: COMPLETED